Muse cells are stress-enduring, pluripotent-like cells discovered by Mari Dezawa's group, infused without HLA matching. Small academic Japanese trials report improved heart function after heart attack, faster ulcer healing in epidermolysis bullosa, and a roughly 40% responder rate in subacute stroke versus 10% on placebo. The anti-aging claims marketed by Eterna Health rest on a two-patient case series measured by an epigenetic clock. No large randomized trial exists for any indication.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Has Muse cell therapy been tested in humans?
Yes, but only in small studies. Japanese academic trials of donor Muse cells (CL2020) report benefits in acute heart attack, epidermolysis bullosa, subacute stroke and ALS, all infused without HLA matching. For anti-aging, the only published human evidence is a two-patient case series from Eterna Health.
Does Muse cell therapy reverse aging?
That claim rests on a 2025 case series of two patients whose biological age dropped on the SystemAge epigenetic clock after IV treatment. There are no controlled trials for longevity or anti-aging, and celebrity patients are not outcome data.
Is Muse cell therapy legal or FDA-approved?
No. It is experimental in the US and Canada and not FDA-approved for anti-aging or longevity. It is offered through medical tourism, mainly in Mexico, with an observational safety study ongoing.
How are Muse cells different from MSCs?
They are isolated by a stress-activation method, carry pluripotency markers such as SSEA-3, and home to damage sites via sphingosine-1-phosphate signaling. The claimed edge over conventional MSCs is low immunogenicity: HLA-mismatched donor cells survive without immunosuppression.
What would change this rating?
Large randomized controlled trials. As of mid-2026 none exist for longevity or anti-aging, and the Japanese disease trials are small and not independently replicated.
02Overview
Muse Cell Therapy (Medical Use of Stretch-activated Natural Cytoplasts) is being marketed by Eterna Health (Dr. Adeel Khan) for longevity, anti-aging, and tissue repair. Zac Efron has been publicly documented as a patient. Muse cells are proposed pluripotent-like cells distinct from conventional MSCs.
03Evidence Taxonomy
In-Vitro: - Muse cells (Multi-lineage differentiating Stress Enduring cells) demonstrate pluripotency markers (SSEA-3, Tra-1-81) and tri-lineage differentiation potential under stress conditions; discovered by Dr. Mari Dezawa (Tohoku University). - Homing via sphingosine-1-phosphate (S1P/S1PR2) bystander signaling documented in cell culture; superior migratory capacity vs conventional MSCs. - Low immunogenicity: HLA-mismatched donor cells survive without immunosuppression in vitro and in vivo (key differentiator).
Animal Models: - Rodent stroke model: IV Muse cells improved functional recovery (Fugl-Meyer, corner-turn tests) vs MSC controls. - Rodent acute MI model: Improved left ventricular ejection fraction (LVEF); durable engraftment without immunosuppressants. - Spinal cord injury and epidermolysis bullosa models: Accelerated tissue repair.
Early Human Evidence (2024–2026): - Japanese CL2020 donor Muse cell trials (academic, peer-reviewed): - Acute MI: Improved LVEF on cardiac MRI. - Epidermolysis bullosa (EB): Accelerated ulcer healing. - Subacute ischemic stroke: Phase I/II — Fugl-Meyer Motor Scale responder rate ~40% vs ~10% placebo (small n). - ALS: ALSFRS-R stabilization trend. - All intravenous, without HLA matching. - Eterna Health (Dr. Adeel Khan, 2025): Case series (n=2) published showing multi-system biological age reversal measured by SystemAge epigenetic clock post IV Muse cell therapy. First claimed "published clinical evidence of age reversal." Clinic operates in Mexico/Canada. - Limitations: No large Phase II/III RCTs for longevity/anti-aging indications as of July 2026; mostly small case series or Japanese academic trials in specific disease indications (stroke, AMI, EB, ALS). - Regulatory: Experimental in US/Canada; not FDA-approved for anti-aging/longevity; offered via medical tourism in Mexico. Ongoing observational safety study.
04Differentiation from MSCs
Muse cells purportedly home more specifically to damage sites and exert effects through paracrine signaling without requiring engraftment. Distinct isolation method (stress-activated).
05Key Players & Claims Audit
- Eterna Health (Dr. Adeel Khan): Longevity Med Summit presentations; claims broad regenerative applications.
- Exposed Risks: Limited independent replication; clinic-level evidence only.
- Zac Efron Documentation: Public mentions but no peer-reviewed outcomes.
06Regulatory & Competitive Landscape
- US FDA: Not approved for anti-aging/longevity indications.
- Competitive: Overlaps with MSC/exosome therapies (see 15-Exosome-Therapy/Exosome Therapy).
- Positioning: Experimental regenerative; emphasize research-stage for clinics.
07Recommended Sections for Expansion
- Full protocol details (if available from sources)
- Safety signals from clinic data
- Comparison table: Muse vs MSC vs Exosomes
08Primary-source focus. Early human evidence only. No medical advice.
Expanded with evidence tiers and regulatory context.
09Connections
10Sources
11Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.